REperfusion With Cooling in CerebraL Acute IscheMia II (RECCLAIM-II)

The purpose of this study is to determine whether reducing a patient's body temperature (mild hypothermia of 33 degrees Centigrade) will significantly reduce the risk of brain injury (notably reperfusion injury and hemorrhagic conversion) in patients who have suffered a significant interruption of blood flow to an area of brain (occlusion of large proximal cerebral artery) and have undergone successful removal of that interruption (revascularization).This will be achieved by comparing patients who have undergone hypothermia to those who have not.

Study Overview

• Status: Withdrawn
• Conditions: Ischemic Stroke; Hypothermia
• Intervention / Treatment: Procedure: Normothermia; Device: Trevo Pro Retriever (Stryker Corp.); Procedure: Mild hypothermia; Device: Zoll Thermogard XP technology with the Quattro catheter

Detailed Description

This study is designed to examine the safety and proof of concept of therapeutic hypothermia prior to conventional revascularization in subjects experiencing acute ischemic stroke by comparing the results to subjects who remain at normal body temperature (normothermic) and proceed directly to reperfusion via conventional reperfusion intervention.

The investigational plan also examines the following outcomes in 85 subjects randomized to either hypothermia or normothermia:

• Regulation of biomarkers indicative of ischemia-reperfusion injury
• Changes in blood brain injury using the Hyperintense Acute Reperfusion Marker (HARM) protocol MRI as a surrogate imaging biomarker
• Incidence of hemorrhagic conversion post reperfusion
• Neurologic function at 90 days post acute ischemic stroke.

The results of this study will be used to power a definitive phase III clinical trial evaluating the combination of hypothermia and revascularization versus reperfusion alone.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Georgia
    • Marietta, Georgia, United States, 30060
      • WellStar Kennestone Regional Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 77 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subjects of any ethnicity and age >/=18 but </= 79 years;
• Symptom onset </=8 hours;
• Symptoms consistent with an ischemic stroke with a large vessel occlusion (Middle Cerebral Artery (MCA), Internal Carotid Artery (ICA) terminus) as determined by CT imaging of the brain;
• Alberta Stroke Program Early CT Score (ASPECTS) of 5-10 on non-contrast CT of the brain;
• Ability to undergo endovascular reperfusion therapy;
• No contraindications to general anesthesia, conscious sedation, or allergies to any components associated with the anticipated diagnostic or treatment procedures that cannot be treated;
• A pre-treatment modified Rankin Scale (mRS) of 0 or 1;
• Baseline CT scan shows no hemorrhage;
• National Institutes of Health Stroke Scale (NIHSS) 14-29;
• Subject has either 1) failed iv tissue plasminogen activator (tPA) therapy or 2) contradicted for iv tPA therapy;
• Subject is capable of complying with study procedures and agrees to complete all required study procedures, study visits and associated activities.
• Subject or legally authorized representative must be able to understand and give written informed consent.

Exclusion Criteria:

• Females of childbearing potential who are pregnant or not using adequate contraception;
• Bleeding diathesis with a platelet count < 50,000 or International Normalized Ratio (INR) >1.7 or any active or recent (within 10 to 30 days) hemorrhage;
• History of genetically confirmed hypercoagulable syndrome;
• Any condition that excludes MRI imaging;
• History of dementia, currently on Aricept or Namenda, or other Alzheimer's-like symptoms;
• End stage renal disease on hemodialysis;
• History of cardiac arrest;
• Presence of an inferior vena cava (IVC) filter;
• Contrast dye allergy with history of anaphylaxis, known serious sensitivity to contrast agents or any condition in which angiography is contraindicated;
• Known allergy to meperidine or buspar;
• Prior neurologic event that would obscure interpretation of the signal and current presenting neurologic deficits;
• Sustained hypertension (systolic blood pressure (SBP) > 185 or diastolic blood pressure (DBP) > 110 refractory to treatment);
• Baseline CT/MRI of head showing evidence of mass effect with mid-line shift, hemorrhage, intracranial tumor, arterial vasculitis or dissection, or bilateral stroke;
• Presence of any other serious comorbidity that would be likely to impact life expectancy to less than 6 months or limit subject cooperation or study compliance;
• Concurrent participation in an investigational clinical study that has not completed the follow-up period or planned participation in another study within the next 3 months;
• Any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete, good quality data or the completion of the research study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Normothermia; As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.	Procedure: Normothermia; Device: Trevo Pro Retriever (Stryker Corp.); Other Names: Clot retrieval, reperfusion; Device: Trevo Pro Retriever (Stryker Corp.); Device: Trevo Pro Retriever (Stryker Corp.)
Experimental: Mild hypothermia; As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.	Device: Trevo Pro Retriever (Stryker Corp.); Device: Trevo Pro Retriever (Stryker Corp.); Procedure: Mild hypothermia; Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.); Other Names: Therapeutic hypothermia, clot retrieval, reperfusion; Device: Zoll Thermogard XP technology with the Quattro catheter; Device: Zoll Thermogard XP technology with the Quattro catheter

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hemorrhagic Conversion	Acute bleeding into the area of the original stroke based on CT or MRI of the head.	48 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events	Evaluation and determination of the following complications pneumonias, central line infections, intra-cerebral hemorrhages, systemic hemorrhages, transient cerebral ischemia, and new strokes.	90 days
Hyperintense Acute Reperfusion Marker (HARM)	HARM is a MRI sequence looking at gadolinium enhancement on FLAIR MRI imaging.	48 +/- 24 hours
National Institutes of Health Stroke Scale (NIHSS)	NIHSS is a scale from 1-42 to evaluate stroke severity	Baseline, 24 +/- 6 hours, 48 +/- 24 hours, 8 +/- 2 days, 90 +/- 15 days
Modified Rankin Scale (mRS)	mRS is a straightforward evaluation of the functional limitations from stroke	Basline, 48 +/- 24 hours, 90 +/- 15 days

Collaborators and Investigators

• Sponsor: WellStar Health System
• Collaborators: Zoll Medical Corporation
• Investigators: Study Director: Rishi Gupta, MD, WellStar Health System

Study record dates

Study Major Dates

• Study Start: February 1, 2016
• Primary Completion (Anticipated): November 1, 2017
• Study Completion (Anticipated): November 1, 2017

Study Registration Dates

• First Submitted: March 25, 2015
• First Submitted That Met QC Criteria: April 7, 2015
• First Posted (Estimate): April 8, 2015

Study Record Updates

• Last Update Posted (Estimate): February 17, 2016
• Last Update Submitted That Met QC Criteria: February 16, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Cardiovascular disease; Stroke; Ischemia; Hypothermia; Acute ischemic stroke; Signs and symptoms; Vascular disease; Brain disease; Brain infarction; Brain ischemia; Cerebral infarction; Mild hypothermia; Cerebrovascular disorder; Central nervous system disease; Nervous system disease; Pathologic process; Body temperature change
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Stroke; Body Temperature Changes; Ischemic Stroke; Ischemia; Hypothermia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents, Local; Anti-Infective Agents; Enzyme Inhibitors; Hormones, Hormone Substitutes, and Hormone Antagonists; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Hormone Antagonists; Antifungal Agents; Steroid Synthesis Inhibitors; 14-alpha Demethylase Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Clotrimazole; Miconazole
• Other Study ID Numbers: RECCLAIM II-S